2022 Fiscal Year Final Research Report
ROCK inhibitor for treating intraocular fibrosis by modulating epithelial-to-mesenchymal transition.
| Project/Area Number |
20K09828
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 56060:Ophthalmology-related
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
松永 直哉 九州大学, 薬学研究院, 教授 (10432915)
武田 篤信 九州大学, 医学研究院, 准教授 (40560313)
中尾 新太郎 独立行政法人国立病院機構九州医療センター(臨床研究センター), その他部局等, 客員研究員 (50583027)
村上 祐介 九州大学, 大学病院, 講師 (50634995)
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | 網膜症 / 糖尿病網膜症 / 網膜剥離 / 形質転換 / リポソーム |
|---|
| Outline of Final Research Achievements |
In this study, the pharmacodynamic properties of liposome-encapsulated ROCK inhibitors were investigated in different animal models. The liposome encapsulation showed significantly improved retention in the eye compared to the non-liposome drug. In addition, in the study of the inhibitory effect on intraocular fibroproliferation, the liposome-encapsulated ROCK inhibitor was found to be effective for a long period of time with fewer intraocular administrations. In addition, the intraocular expression of periostin, a biomarker that reflects intraocular fibrosis, was also significantly suppressed by the liposomal formulation.
|
| Free Research Field |
眼科学
|
| Academic Significance and Societal Importance of the Research Achievements |
眼内線維増殖に対する薬剤は、未だ臨床応用されておらず新規治療薬開発が望まれている。今回の研究成果により、眼内線維増殖抑制が期待されるROCK阻害薬の臨床応用に向けて、リポソーム化修飾することで、頻回の眼内注射を避けることができる可能性が示された。
|
